Investigating a new Dillenia ovata endophytic bacteria to produce antioxidants and anti-diabetes activity in vitro and in vivo

Q1 Immunology and Microbiology

Biotechnology Reports Pub Date : 2025-08-20 DOI:10.1016/j.btre.2025.e00921

Linh Chi Tran , Chong Kim Thien Duc , Tuan Trong Nguyen , Duy Toan Pham , Danh Thai Luu , Trang Thi Xuan Dai

{"title":"Investigating a new Dillenia ovata endophytic bacteria to produce antioxidants and anti-diabetes activity in vitro and in vivo","authors":"Linh Chi Tran , Chong Kim Thien Duc , Tuan Trong Nguyen , Duy Toan Pham , Danh Thai Luu , Trang Thi Xuan Dai","doi":"10.1016/j.btre.2025.e00921","DOIUrl":null,"url":null,"abstract":"<div><div>A novel endophytic bacterium, <em>Bacillus</em> sp. DO-R5, with strong antioxidant and anti-diabetic properties, was isolated from <em>Dillenia ovata</em>, a traditional Vietnamese medicinal plant. <em>Bacillus</em> sp. DO-R5 was identified using morphological characteristics, SEM, and <em>16S rRNA</em> sequencing, demonstrated the highest bioactivity among the 19 isolates. Optimal fermentation conditions (8.9 g/L D-glucose, pH 7.5, 38 °C, and 70.5 h) were determined using the Box-Behnken design. Under these conditions, <em>Bacillus</em> sp. DO-R5 significantly enhanced the production of bioactive compounds including diosmin, rutin, and chlorogenic acid, and exhibited improved <em>in vitro</em> antioxidant, anti-inflammatory, and anti-diabetic activities. <em>In vivo</em>, the extract effectively reduced blood glucose, regulated lipid profiles, supported weight control, and protected organs. These findings emphasize the potential therapeutic use of <em>D. ovata</em> endophytic bacteria as a natural source of anti-diabetic drugs.</div></div>","PeriodicalId":38117,"journal":{"name":"Biotechnology Reports","volume":"48 ","pages":"Article e00921"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2215017X25000487","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

Abstract

A novel endophytic bacterium, Bacillus sp. DO-R5, with strong antioxidant and anti-diabetic properties, was isolated from Dillenia ovata, a traditional Vietnamese medicinal plant. Bacillus sp. DO-R5 was identified using morphological characteristics, SEM, and 16S rRNA sequencing, demonstrated the highest bioactivity among the 19 isolates. Optimal fermentation conditions (8.9 g/L D-glucose, pH 7.5, 38 °C, and 70.5 h) were determined using the Box-Behnken design. Under these conditions, Bacillus sp. DO-R5 significantly enhanced the production of bioactive compounds including diosmin, rutin, and chlorogenic acid, and exhibited improved in vitro antioxidant, anti-inflammatory, and anti-diabetic activities. In vivo, the extract effectively reduced blood glucose, regulated lipid profiles, supported weight control, and protected organs. These findings emphasize the potential therapeutic use of D. ovata endophytic bacteria as a natural source of anti-diabetic drugs.

查看原文本刊更多论文

研究一种新的卵形莲内生细菌在体外和体内产生抗氧化剂和抗糖尿病活性

摘要从越南传统药用植物紫莲中分离到一株具有较强抗氧化和抗糖尿病活性的内生细菌DO-R5。通过形态学特征、扫描电镜（SEM）和16S rRNA测序对DO-R5菌株进行鉴定，发现其生物活性最高。采用Box-Behnken设计确定最佳发酵条件（8.9 g/L D-glucose, pH 7.5, 38°C, 70.5 h）。在这些条件下，芽孢杆菌sp. DO-R5显著提高了地奥米、芦丁和绿原酸等生物活性物质的产量，并表现出较好的体外抗氧化、抗炎和抗糖尿病活性。在体内，提取物有效地降低血糖，调节血脂，支持体重控制和保护器官。这些发现强调了ovata内生细菌作为抗糖尿病药物的天然来源的潜在治疗用途。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biotechnology Reports Immunology and Microbiology-Applied Microbiology and Biotechnology

CiteScore

15.80

自引率

0.00%

发文量

审稿时长

55 days

期刊介绍： Biotechnology Reports covers all aspects of Biotechnology particularly those reports that are useful and informative and that will be of value to other researchers in related fields. Biotechnology Reports loves ground breaking science, but will also accept good science that can be of use to the biotechnology community. The journal maintains a high quality peer review where submissions are considered on the basis of scientific validity and technical quality. Acceptable paper types are research articles (short or full communications), methods, mini-reviews, and commentaries in the following areas: Healthcare and pharmaceutical biotechnology Agricultural and food biotechnology Environmental biotechnology Molecular biology, cell and tissue engineering and synthetic biology Industrial biotechnology, biofuels and bioenergy Nanobiotechnology Bioinformatics & systems biology New processes and products in biotechnology, bioprocess engineering.